Poll Results Spotlight Key GU Cancer Abstracts Driving Anticipation Ahead of ESMO 2025

In the lead-up to the 2025 ESMO Congress, excitement is mounting around several key datasets expected to influence future standards of care across prostate, kidney, and bladder cancers.

To gauge expert interest ahead of the meeting, OncLive® conducted polls on both X and LinkedIn to determine which genitourinary (GU) cancer abstracts and disease areas oncology specialists were most eager to learn about.

Poll Results

On X, 57.1% of 7 total respondents selected the phase 3 ENZARAD trial (NCT02446444) in prostate cancer as the most anticipated presentation, followed by the phase 3 RAMPART trial (NCT03288532) in renal cell carcinoma (RCC; 28.6%) and substudy 03A of the phase 1/2 KEYMAKER-U03 trial (NCT04626479) in RCC (14.3%); no votes were cast for the phase 3 ALBAN trial (NCT03799835) in non–muscle-invasive bladder cancer (NMIBC). On LinkedIn, ENZARAD similarly captured 57% of 7 total votes, with KEYMAKER-U03 (29%) and ALBAN (14%) rounding out interest; RAMPART received no votes.

When asked which GU cancer specialty they were most interested in during ESMO 2025, 50% of the 8 total respondents on X selected RCC, followed by bladder cancer (37.5%) and prostate cancer (12.5%). On LinkedIn, bladder cancer received the most votes (55%) among 33 total respondents, followed by prostate cancer (24%), and RCC (21%).

Based on these poll results, OncLive has assembled an overview of the most highly anticipated abstracts. Read on for a closer look at each study.

LBA86: Randomised Phase 3 trial of Androgen Deprivation Therapy (ADT) With Radiation Therapy With or Without Enzalutamide for High Risk, Clinically Localized Prostate Cancer: ENZARAD (ANZUP 1303)

Presentation time: Sun, October 19, 2025, 10:15-10:25pm CET

ENZARAD is a randomized, multicenter study evaluating the addition of enzalutamide (Xtandi) to androgen deprivation therapy (ADT) with a luteinizing hormone–releasing hormone analogue and external beam radiotherapy vs conventional nonsteroidal anti-androgen therapy plus ADT and radiotherapy in patients with high-risk, clinically localized prostate cancer.1

Previously reported baseline characteristics from the study showed that among 802 patients enrolled in the trial, the median age was 71 years; most patients (52%) had a Gleason score of 9; and 45%, 42%, and 11% of patients had cT3, cT2, and cN1 disease, respectively.2

LBA96: First-Line Pembrolizumab-Based Regimens for Advanced Clear Cell Renal Cell Carcinoma: KEYMAKER-U03 Substudy 03A

Presentation time: Sat, October 18, 2025, 8:30-8:40am CET

KEYMAKER-U03 is a global, adaptive, randomized umbrella study evaluating a variety of combination regimens across multiple substudies in patients with advanced RCC across lines of therapy.3,4 Substudy 03A is designed to assess the safety and efficacy of investigational combinations including pembrolizumab (Keytruda), quavonlimab (NK-1308), lenvatinib (Lenvima), favezelimab (MK-4280), belzutifan (Welireg), and vibostolimab (MK-7684) in the first-line setting in patients with advanced clear cell RCC (cRCC).3

Previously reported findings from the KEYMAKER-U03 substudy 03B (NCT04626518) showed the clinical activity of lenvatinib plus belzutifan, pembrolizumab plus lenvatinib, and pembrolizumab plus belzutifan in pretreated patients with advanced ccRCC.4

LBA93: First Results from RAMPART: An International Phase 3 Randomised-Controlled Trial of Adjuvant Durvalumab Monotherapy or Combined With Tremelimumab for Resected Primary Renal Cell Carcinoma (RCC) Led By MRC CTU at UCL

Presentation time: Sat, October 18, 2025, 9:20-9:30am CET

RAMPART is a multi-arm, randomized, multi-stage platform study evaluating adjuvant durvalumab (Imfinzi) monotherapy or durvalumab plus tremelimumab (Imjudo) vs active monitoring in patients with resected RCC at intermediate or high risk of recurrence.5 Patients with Leibovich scores 3 to 11 were eligible for random assignment, with accrual of intermediate-risk patients (scores 3-5) capped at 25% of the total enrollment or 3 years, whichever occurs first; recruitment of high-risk patients (scores 6-11) was designed to continue until the overall accrual target was reached.

Patients were randomly assigned to receive active monitoring for 1 year (arm A), durvalumab at 1500 mg every 4 weeks for a maximum of 13 cycles (arm B), or durvalumab at the same dosing schedule plus tremelimumab at 75 mg at the start of durvaluamb cycles 1 and 2 (arm C). The coprimary end points are disease-free survival and overall survival.

LBA107: A Phase 3, Randomized, Open-Label, International Study of Intravenous (IV) Atezolizumab and Intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG-Naïve High-Risk, Non-Muscle-Invasive Bladder Cancer (NMIBC)

Presentation time: Fri, October 17, 2025, 2:00-2:10pm CET

ALBAN is an open-label, randomized, multicenter study evaluating intravesical BCG alone vs BCG plus atezolizumab (Tecentriq) in patients with high-risk, BCG-naive NMIBC.6 The study enrolled 517 patients across 45 centers in France, Belgium, and Spain. The primary end point is event-free survival.

Want to learn more about these studies? Visit our conference coverage page during the meeting for real-time updates on these presentations and more!

References

1. Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer (ENZARAD). Clinicalltrials.gov. Updated May 30, 2025. Accessed September 25, 2025. https://www.clinicaltrials.gov/study/NCT02446444
2. Niazi T, Nguyen PL, Williams S, et al. Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa). J Clin Oncol. 2024;42(suppl 4):328. doi:10.1200/JCO.2024.42.4_suppl.328
3. Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A). ClinicalTrials.gov. Updated February 17, 2025. Accessed September 26, 2025. https://www.clinicaltrials.gov/study/NCT04626479
4. Albiges L, Suárez C, Powles T, et al. KEYMAKER-U03 substudy 03B: pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2025;43(suppl 5):440. doi:10.1200/JCO.2025.43.5_suppl.440
5. Renal adjuvant multiple arm randomised trial (RAMPART). Clinicaltrials.gov Updated September 7, 2020. Accessed September 25, 2025. https://www.clinicaltrials.gov/study/NCT03288532
6. Atezolizumab plus one-year bcg bladder instillation in bcg-naive high-risk non-muscle invasive bladder cancer patients (ALBAN). Clinicaltrials.gov Updated December 11, 2024. Accessed September 25, 2025. https://clinicaltrials.gov/study/NCT03799835